ReviewJournal of hematology & oncology2016
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Review in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Haploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: a multicenter, randomized, open-label, phase 3 trial.Signal transduction and targeted therapy · 2024Trial
- Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.American journal of hematology · 2024Trial
- Improved function and balance in T cell modulation by endothelial cells in young people.Clinical and experimental immunology · 2021Trial
- Different subsets of haematopoietic cells and immune cells in bone marrow between young and older donors.Clinical and experimental immunology · 2021Trial
- Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.Blood advances · 2020Trial
- Trial
- Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD.International journal of hematology · 2019Trial
- Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.Journal of immunology research · 2017Trial
- Alternative donors, particularly haploidentical donors, are safe and effective for elderly patients with adverse-risk AML: a multicenter TROPHY study.Blood cancer journal · 2026Article
- [Impact of donor characteristics on prognosis for myelodysplastic syndromes after haplo-identical transplantation: a retrospective study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation.Leukemia · 2025Article
- Recipient-specific antibodies in HSCT: current knowledge and future perspectives.Frontiers in immunology · 2025Article
- Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donorChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know.Oncology and therapy · 2024Review
- The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome.Clinical and experimental medicine · 2024Article
- Human leukocyte antigen evolutionary divergence as a novel risk factor for donor selection in acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation.Frontiers in immunology · 2024Article
- Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.Bone marrow transplantation · 2023Article
- [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide.Bone marrow transplantation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can significantly impact the incidences of acute and chronic graft-versus-host disease, transplant-related mortality, and relapse, in addition to overall survival. In this review, we focused on factors associated with transplant outcomes following unmanipulated haplo-SCT with anti-thymocyte globulin (ATG) or after T-cell-replete haplo-SCT with post-transplantation cyclophosphamide (PT/Cy). We summarized the effects of the primary factors, including donor-specific antibodies against human leukocyte antigens (HLA); donor age and gender; killer immunoglobulin-like receptor-ligand mismatches; and non-inherited maternal antigen mismatches. We also offered some expert recommendations and proposed an algorithm for selecting donors for unmanipulated haplo-SCT with ATG and for T-cell-replete haplo-SCT with PT/Cy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.